21 publications

Name Date Type Actions

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

 		29/04/2024 Public releases

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

 		24/04/2024 Public releases

Buyback programs - March 2024

Monthly communication regarding buyback programs

04/04/2024 Description of buyback programs

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

 		20/03/2024 Public releases

Buyback programs – January 2024

Monthly communication regarding buyback programs

02/02/2024 Description of buyback programs

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

 		24/01/2024 Public releases

Vétoquinol announces opening of its first decentralized R&D center in Canada

 		17/12/2007 Public releases

Vétoquinol to market and distribute Vetprofen in the United States

 		28/11/2007 Public releases

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

 		25/10/2007 Public releases

Reports very good first half, confirming that 2007 performance is set to surpass targets

 		27/09/2007 Public releases